Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/10/10/350 |
| _version_ | 1797759947270782976 |
|---|---|
| author | Marco Rastrelli Beatrice Ferrazzi Francesco Cavallin Vanna Chiarion Sileni Jacopo Pigozzo Alessio Fabozzi Saveria Tropea Antonella Vecchiato Alessandra Costa Alessandro Parisi Carlo Riccardo Rossi Paolo Del Fiore Mauro Alaibac |
| author_facet | Marco Rastrelli Beatrice Ferrazzi Francesco Cavallin Vanna Chiarion Sileni Jacopo Pigozzo Alessio Fabozzi Saveria Tropea Antonella Vecchiato Alessandra Costa Alessandro Parisi Carlo Riccardo Rossi Paolo Del Fiore Mauro Alaibac |
| author_sort | Marco Rastrelli |
| collection | DOAJ |
| description | Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival. |
| first_indexed | 2024-03-12T18:51:49Z |
| format | Article |
| id | doaj.art-a6b4871d3ece4c9388cb86632451f38a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T18:51:49Z |
| publishDate | 2018-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a6b4871d3ece4c9388cb86632451f38a2023-08-02T07:12:31ZengMDPI AGCancers2072-66942018-09-01101035010.3390/cancers10100350cancers10100350Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 PatientsMarco Rastrelli0Beatrice Ferrazzi1Francesco Cavallin2Vanna Chiarion Sileni3Jacopo Pigozzo4Alessio Fabozzi5Saveria Tropea6Antonella Vecchiato7Alessandra Costa8Alessandro Parisi9Carlo Riccardo Rossi10Paolo Del Fiore11Mauro Alaibac12Surgical Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, 35121 Padua, ItalyDermatology Unit and Pathology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, ItalyIndependent Statistician, 35121 Solagna, ItalyMelanoma and Esophagus Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35121 Padua, ItalyMelanoma and Esophagus Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35121 Padua, ItalyMelanoma and Esophagus Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35121 Padua, ItalySurgical Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, 35121 Padua, ItalySurgical Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, 35121 Padua, ItalySurgical Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, 35121 Padua, ItalyRadiotherapy Unit, Veneto Institute of Oncology, IOV–IRCCS, 35121 Padua, ItalySurgical Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, 35121 Padua, ItalySurgical Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, 35121 Padua, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padova, 35128 Padua, ItalyMerkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.http://www.mdpi.com/2072-6694/10/10/350Merkel cell carcinomaneuroendocrine neoplasmskin neoplasmsurvivalCK20 expressionimmunomodulatory drugs |
| spellingShingle | Marco Rastrelli Beatrice Ferrazzi Francesco Cavallin Vanna Chiarion Sileni Jacopo Pigozzo Alessio Fabozzi Saveria Tropea Antonella Vecchiato Alessandra Costa Alessandro Parisi Carlo Riccardo Rossi Paolo Del Fiore Mauro Alaibac Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients Cancers Merkel cell carcinoma neuroendocrine neoplasm skin neoplasm survival CK20 expression immunomodulatory drugs |
| title | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
| title_full | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
| title_fullStr | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
| title_full_unstemmed | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
| title_short | Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients |
| title_sort | prognostic factors in merkel cell carcinoma a retrospective single center study in 90 patients |
| topic | Merkel cell carcinoma neuroendocrine neoplasm skin neoplasm survival CK20 expression immunomodulatory drugs |
| url | http://www.mdpi.com/2072-6694/10/10/350 |
| work_keys_str_mv | AT marcorastrelli prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT beatriceferrazzi prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT francescocavallin prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT vannachiarionsileni prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT jacopopigozzo prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT alessiofabozzi prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT saveriatropea prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT antonellavecchiato prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT alessandracosta prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT alessandroparisi prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT carloriccardorossi prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT paolodelfiore prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients AT mauroalaibac prognosticfactorsinmerkelcellcarcinomaaretrospectivesinglecenterstudyin90patients |